Polyrotaxane-based Supramolecular Theranostics

Guocan Yu,Zhen Yang,Xiao Fu,Bryant C Yung,Jie Yang,Zhengwei Mao,Li Shao,Bin Hua,Yijing Liu,Fuwu Zhang,Quli Fan,Sheng Wang,Orit Jacobson,Albert Jin,Changyou Gao,Xiaoying Tang,Feihe Huang,Xiaoyuan Chen
DOI: https://doi.org/10.1038/s41467-018-03119-w
IF: 16.6
2018-01-01
Nature Communications
Abstract:The development of smart theranostic systems with favourable biocompatibility, high loading efficiency, excellent circulation stability, potent anti-tumour activity, and multimodal diagnostic functionalities is of importance for future clinical application. The premature burst release and poor degradation kinetics indicative of polymer-based nanomedicines remain the major obstacles for clinical translation. Herein we prepare theranostic shell-crosslinked nanoparticles (SCNPs) using a β-cyclodextrin-based polyrotaxane (PDI-PCL-b-PEG-RGD⊃β-CD-NH2) to avoid premature drug leakage and achieve precisely controllable release, enhancing the maximum tolerated dose of the supramolecular nanomedicines. cRGDfK and perylene diimide are chosen as the stoppers of PDI-PCL-b-PEG-RGD⊃β-CD-NH2, endowing the resultant SCNPs with excellent integrin targeting ability, photothermal effect, and photoacoustic capability. In vivo anti-tumour studies demonstrate that drug-loaded SCNPs completely eliminate the subcutaneous tumours without recurrence after a single-dose injection combining chemotherapy and photothermal therapy. These supramolecular nanomedicines also exhibit excellent anti-tumour performance against orthotopic breast cancer and prevent lung metastasis with negligible systemic toxicity.
What problem does this paper attempt to address?